Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/01/2003EP1348033A2 Reagents and methods for identifying and modulating expression of genes regulated by retinoids
10/01/2003EP1348029A2 Materials and methods relating to protein aggregation in neurodegenerative disease
10/01/2003EP1348027A2 Gene disruption methodologies for drug target discovery
10/01/2003EP1348026A2 Fibrin binding moieties useful as imaging agents
10/01/2003EP1348022A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/01/2003EP1347987A1 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
10/01/2003EP1347980A1 Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof
10/01/2003EP1347971A1 Thiazolyl inhibitors of tec family tyrosine kinases
10/01/2003EP1347805A2 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
10/01/2003EP1347780A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides
10/01/2003EP1347779A2 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
10/01/2003EP1347778A1 Behavior chemotherapy
10/01/2003EP1347776A2 Anti-inflammatory use of polycationic compounds
10/01/2003EP1347773A2 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
10/01/2003EP1347771A2 Methods of using imxp-888 and imxp-888 antagonists
10/01/2003EP1347766A2 Composition for the treatment of osteoarthritis
10/01/2003EP1347762A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
10/01/2003EP1347761A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/01/2003EP1347755A2 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
10/01/2003EP1347753A1 Topical composition and method for treating urinary stress incontinence
10/01/2003EP1347752A2 Anti-proliferative drugs
10/01/2003EP1347751A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
10/01/2003EP1347750A1 Treatment of male sexual dysfunction
10/01/2003EP1347745A2 Dietary composition containing conjugated linoleic acid and calcium for improved health
10/01/2003EP1347730A2 Recombinant anti-cd30 antibodies and uses thereof
10/01/2003EP1202954B1 Novel aminobenzophenones
10/01/2003EP1056467B1 Method for the treatment of diseases or disorders of the inner ear
10/01/2003EP1037666B1 Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
10/01/2003EP1000029B1 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
10/01/2003EP0999854B1 Switchable viscoelastic systems containing galactomannan polymers and borate
10/01/2003EP0999825B1 Ophthalmic compositions containing galactomannan polymers and borate
10/01/2003EP0977558B1 Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
10/01/2003EP0914043B1 Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
10/01/2003EP0904056B1 Process and device for inhalation of particulate medicaments
10/01/2003EP0891331B1 N-(2 oxoacetyl or sulphonyl)-pyrrolidine/piperidine-2-carboxylic acid derivatives with improved multi-drug resistance activity
10/01/2003CN1446265A Means and method for monitoring antiretroviral therapy and guiding therapeutic decisions in treatment of HIV/AIDS
10/01/2003CN1446261A Modified cytokines for use in cancer therapy
10/01/2003CN1446229A Somatostatin analogues
10/01/2003CN1446228A 校正基因 Correction gene
10/01/2003CN1446227A Novel fibroblast growth factor (FRF23) and method for use
10/01/2003CN1446213A Medicinal compositions containing propenone derivatives
10/01/2003CN1446201A Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
10/01/2003CN1446197A Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
10/01/2003CN1446108A Pharmaceutical form comprising a support material and at least a cell regulating factor and/or cell proliferation promoter
10/01/2003CN1446106A Method of treating estrogen receptor positive carcinoma
10/01/2003CN1446104A Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
10/01/2003CN1446101A Combination product comprising melagatran and factor VLLa inhibitor
10/01/2003CN1446100A Method for treating movement disorder
10/01/2003CN1446098A Modulation of alpha-6 integrin-mediated responses
10/01/2003CN1446093A Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity
10/01/2003CN1446091A Daily treatment for erectile dysfunction using PDES inhibitor
10/01/2003CN1446087A Use of lipase inhibitors
10/01/2003CN1446084A Treatment of insulin resistance syndrome
10/01/2003CN1446080A Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
10/01/2003CN1446079A Liposomal antineoplastic drugs and uses thereof
10/01/2003CN1444926A Bio-adhesiveness drug release system
10/01/2003CN1122534C Method for reducing side effects of drug
09/2003
09/30/2003US6627754 Pyrrolo[2,3-d]pyrimidine compounds
09/30/2003US6627747 Essential bacterial genes and their use
09/30/2003US6627739 Antibodies having preferential binding to proteases; screening for enzyme inhibitors used in therapy of neurodegenerative diseases, such as Alzheimer's disease
09/30/2003US6627661 Use of 5HT-6 antagonists
09/30/2003US6627656 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
09/30/2003US6627653 Anticonvulsant derivatives useful for the treatment of depression
09/30/2003US6627652 Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
09/30/2003US6627625 Beta-lactam antibiotics and beta -lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter by anxiolytic and antiaggressive behavior modification ans enhanced cognition
09/30/2003US6627614 Treating a patient having a disease associated with undesirable or uncontrolled cell proliferation. The method comprises: administering to the patient an anthracycline for a period of time during which a 20(S)-camptothecin is not
09/30/2003US6627605 Polynucleotides which encode them, and methods for their use. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention further provides methods for diagnosing or treating disorders with
09/30/2003US6627602 Preventing desensitization of receptors
09/30/2003US6627415 Isolated nucleic acid comprising a nucleotide sequence encoding fibrinogen-like domain; use in diagnosis and treatment of tumor angiogenesis, wound healing, thromboembolic diseases, atherosclerosis and inflammationinflammation
09/30/2003US6627222 Amoxicillin-dicloxacillin antibiotic composition
09/30/2003US6627211 Vehicle containing alcohol, glycol and biological surfactant
09/30/2003US6627210 Alpha-2-adrenergic agonist component is selected from the group consisting of imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines and derivatives or mixtures
09/30/2003US6627195 Binding agents to CD23
09/30/2003CA2406592C Method of preparing pharmaceutical dosage forms containing multiple active ingredients
09/30/2003CA2133759C Evaluation and treatment of patients with progressive immunosuppression
09/30/2003CA2123321C Combination chemotherapy
09/30/2003CA2106073C Composition for promoting tissue repair and regeneration
09/30/2003CA2099585C Pharmaceutical compositions
09/30/2003CA2041579C Dosage form
09/25/2003WO2003079025A2 Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
09/25/2003WO2003079020A2 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
09/25/2003WO2003078632A1 Novel receptor polypeptides and polynucleotides encoding the same
09/25/2003WO2003078630A1 INHIBITION OF THE β3 SUBUNIT OF L-TYPE CA2+ CHANNELS
09/25/2003WO2003078579A2 Compositions and methods for treating emphysema
09/25/2003WO2003078465A1 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
09/25/2003WO2003078438A1 Carbamates as hiv protease inhibitors
09/25/2003WO2003078437A1 Methods and compositions comprising nitric oxide donors and opioid analgesics
09/25/2003WO2003078428A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs
09/25/2003WO2003078411A1 C3-cyano epothilone derivatives
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078376A1 Nk1 antagonists
09/25/2003WO2003077999A1 Combination ofa cdk inhibitor and 5-fu for the treatment of cancer
09/25/2003WO2003077998A1 Use of asc-1 inhibitors to treat neurological and psychiatric disorders
09/25/2003WO2003077952A1 Topical composition comprising a cyclofructan, a carrier and a drug
09/25/2003WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors
09/25/2003WO2003077935A1 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
09/25/2003WO2003077932A1 Remedies for lung cancer
09/25/2003WO2003077930A1 Use of at least one quercetine flavonoid for increasing the level of useful short-chain fatty acids in the lower intestinal tract
09/25/2003WO2003077929A1 Fosinopril formulation
09/25/2003WO2003077928A1 Peptide analogues and uses thereof
1 ... 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 ... 1151